Fineline Cube

Follow:
14486 Articles
HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes
CompanyDrug

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Others

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
CompanyDeals

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Company

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
CompanyDeals

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
CompanyDeals

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
CompanyDeals

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite

ModeX Therapeutics Partners With Regeneron on Multispecific Antibody Platform
CompanyDeals

ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
CompanyDeals

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch

Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
CompanyDrug

Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
CompanyDrug

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
CompanyDeals

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal